CIK 0001000694
- Large accelerated filer
NOVAVAX INC
Sign in to watch- Ticker
- NVAX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 222816046
- Phone
- +1 240-268-2000
- Business address
- 21 FIRSTFIELD RD, GAITHERSBURG, MD
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-01-05 | Trizzino John EVP, CMO and CBO | Exercise or conversion · Stock Option (Right to Buy) | −2,214 | 0 | ||
| 2021-01-05 | Trizzino John EVP, CMO and CBO | Exercise or conversion · Stock Option (Right to Buy) | −1,668 | 5,009 | ||
| 2021-01-05 | Trizzino John EVP, CMO and CBO | Exercise or conversion · Stock Option (Right to Buy) | −2,082 | 12,507 | ||
| 2021-01-05 | Trizzino John EVP, CMO and CBO | Exercise or conversion · Stock Option (Right to Buy) | −6,249 | 68,751 | ||
| 2021-01-05 | Trizzino John EVP, CMO and CBO | Exercise or conversion · Stock Appreciation Right | −1,149 | 12,651 | ||
| 2021-01-01 | YOUNG JAMES F Director | Exercise or conversion | +10,000 | 10,000 | ||
| 2021-01-01 | YOUNG JAMES F Director | Exercise or conversion · Restricted Stock Units | −10,000 | 10,000 | ||
| 2020-12-31 | DOUGLAS RICHARD Director | Exercise or conversion | +1,000 | $50.00 | $50K | 28,500 |
| 2020-12-31 | DOUGLAS RICHARD Director | Exercise or conversion · Stock Option (Right to Buy) | −1,000 | 0 | ||
| 2020-12-31 | YOUNG JAMES F Director | Exercise or conversion | +1,000 | $50.00 | $50K | 1,000 |
| 2020-12-31 | YOUNG JAMES F Director | Exercise or conversion | +10,000 | $51.40 | $514K | 11,000 |
| 2020-12-31 | YOUNG JAMES F Director | Sale | −9,000 | $112.98 | $1.0M | 2,000 |
| 2020-12-31 | YOUNG JAMES F Director | Sale | −2,000 | $113.60 | $227K | 0 |
| 2020-12-31 | YOUNG JAMES F Director | Exercise or conversion · Stock Option (Right to Buy) | −1,000 | 0 | ||
| 2020-12-31 | YOUNG JAMES F Director | Exercise or conversion · Stock Option (Right to Buy) | −10,000 | 0 | ||
| 2020-12-14 | Herrmann John A III EVP, Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +12,700 | 12,700 | ||
| 2020-12-14 | Herrmann John A III EVP, Chief Legal Officer | Grant or award · Restricted Stock Units | +6,300 | 6,300 | ||
| 2020-12-14 | Trizzino John EVP, CMO and CBO | Grant or award · Stock Option (Right to Buy) | +9,500 | 9,500 | ||
| 2020-12-14 | Trizzino John EVP, CMO and CBO | Grant or award · Restricted Stock Units | +4,800 | 4,800 | ||
| 2020-12-14 | Glenn Gregory M President, R&D | Grant or award · Stock Option (Right to Buy) | +18,700 | 18,700 |
Page 74 of 87 · 1,734 trades